| Monoclonal antibody | |
|---|---|
| Source | Human |
| CD4 | |
| Identifiers | |
| CAS number | 680188-33-4 |
| ATC code | none |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ibalizumab (TMB-355[1] previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process.[2] It is being investigated as an HIV entry inhibitor[3] with the ability to block both CCR5- and CXCR4-tropic viruses,[4] and is currently undergoing a Phase II clinical trial with an estimated study completion date in October 2010.[5]
Results from a previous Phase II of ibalizumab, reported by the original developer Tanox in 2006,[4] showed that HIV-infected patients who received the drug, in combination with an optimized background regimen (OBR), maintained a considerably greater reduction in viral load and experienced a statistically significant increase in CD4+ cells than did patients given placebo in combination with OBR.
Development
Ibalizumab is currently being developed by TaiMed Biologics but was originally developed by Tanox, now part of Genentech. As part of Genentech's takeover of Tanox, the patent for ibalizumab was sold to TaiMed Biologics, a biotech company formed in 2007 with support from the Taiwanese Government through a $20 million investment by the state-owned National Development Fund.[6][7][8]
See also
References
- ^ Ibalizumab (TMB-355), TaiMed Biologics, 2009-09-09
- ^ Jacobson JM, Kuritzkes DR, Godofsky E, et al. (February 2009). "Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults". Antimicrob. Agents Chemother. 53 (2): 450–7. doi:. PMID 19015347. http://aac.asm.org/cgi/pmidlookup?view=long&pmid=19015347.
- ^ TNX-355 fact sheet, AIDSmeds.com, 2006-08-25
- ^ a b Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial, AEGiS, 2006-05-02
- ^ Dose-Response Study of Ibalizumab + OBR in Patients With HIV-1, ClinicalTrials.gov, 2008-10-30
- ^ Genentech Partners with Taiwan Company on AIDS Drug Seeking Alpha, 2007-09-18
- ^ Government pushes biotech industry, Taipei Times, 2007-09-15
- ^ Tanox's AIDS Drug Survives, BioHouston, 2008-04-11
|
|||||||||||||||||||||||||||||||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
